Initial Therapeutics

Executive Summary

Initial Therapeutics is a preclinical-stage biotechnology company pioneering novel RNA-targeted medicines for severe neurological and rare diseases. Founded in 2021 and headquartered in San Francisco, the company has raised $75 million to develop its proprietary platform that engages previously undruggable RNA structures, enabling modulation of disease biology in genetically defined disorders with high unmet need. With a focus on neuroscience and rare disease, Initial Therapeutics aims to address conditions where traditional small molecules or biologics have failed. The company's approach leverages RNA structure-based drug discovery to create precise therapies, positioning it to potentially transform treatment paradigms in areas with limited options. As a private, preclinical entity, Initial Therapeutics represents an early-stage investment opportunity with significant upside if its platform validates in upcoming studies. The company's success hinges on advancing lead programs toward clinical development and demonstrating target engagement in animal models. Given the early stage, conviction is moderate, reflecting the high technical risk inherent in novel RNA-targeted modalities but also the substantial market potential in neurology and rare diseases.

Upcoming Catalysts (preview)

• H1 2027Lead Program IND-Enabling Studies40% success
• 2026Series B or Additional Financing70% success
• 2026Platform Validation Data Publication50% success